MedTrace Logo

Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans

NCT01762046 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1033

Last updated 2026-05-06

Study results available
· View outcomes & findings →

Summary

The SUGAR-MGH investigators are studying the influence of inherited gene variants on the response to two commonly prescribed type 2 diabetes medications, metformin and glipizide. They hypothesize that variants in genes that are associated with type 2 diabetes or related traits may impact the effect of anti-diabetic medications. In addition, physiological responses to an insulin secretagogue or an insulin sensitizer may shed light on the mechanism of action of reported genetic associations.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Glipizide

DRUG

Metformin

OTHER

Oral Glucose Tolerance Test

Sponsors & Collaborators

  • Brigham and Women's Hospital

    collaborator OTHER

  • Joslin Diabetes Center

    collaborator OTHER

  • Broad Institute of MIT and Harvard

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Jose C Florez, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2015-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01762046 on ClinicalTrials.gov